| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8f172a6d6eb56f0767ad34cb9820be7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4cb16cf58d4a2ebbc4f3a25c8ad03c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06baeec42fb31c4e8de50fea8dd513e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_794f888416a502cb1c52e15e056d2b11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3488ac22f7fc64da7b7be0adfeadb640 |
| publicationDate |
2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2675291-A1 |
| titleOfInvention |
Killer ig-like receptor (kir) antibodies, formulations, and uses thereof |
| abstract |
Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activation of NK cell cytotoxicity required to clear cancer cells and other diseased cells in a subject. An IgG4 isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NK cell activation and, thus, potentiates NK cell-mediated cytotoxicity. The pharmacokinetics and pharmacodynamics of 1-7F9 is assessed in pre-clinical and clinical trials in order to determine a dosing frequency that is effective to potentiate NK cell cytotoxicity (i.e., modulate NK cells and/or treat cancer). |
| priorityDate |
2007-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |